Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)	Genital Diseases, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, bronchial neoplasm, bronchogenic carcinoma, carcinoma, epithelial neoplasm, lung disorder, lung neoplasm, male reproductive organ cancer, male reproductive system disorder, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, primitive neuroectodermal tumor, prostate cancer, prostate disorder, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma	Active, not recruiting	Phase 1 / Phase 2	2026-02-24		NCT04471727
Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)	Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease	Active, not recruiting	Phase 1	2025-12-05		NCT04184050

Clinical trials